Skip to main content
PMC home page
The BMJ logoLink to The BMJ
. 1991 Nov 9;303(6811):1159–1162. doi: 10.1136/bmj.303.6811.1159

Relation of coronary heart disease and apolipoprotein E phenotype in patients with non-insulin dependent diabetes.

M Laakso 1, A Kesäniemi 1, K Kervinen 1, M Jauhiainen 1, K Pyörälä 1
PMCID: PMC1671489  PMID: 1747611

Abstract

OBJECTIVES--To examine the relation between coronary heart disease and the apolipoprotein E phenotypes in patients with non-insulin dependent diabetes mellitus. DESIGN--Cross sectional study. SETTING--District around Kuopio University Central Hospital, East Finland. SUBJECTS--138 men with non-insulin dependent diabetes and 64 men without diabetes as controls. MAIN OUTCOME MEASURE--Apolipoprotein E phenotype, electrocardiographic abnormalities, other signs of coronary heart disease. RESULTS--The prevalences of definite myocardial infarction and ischaemic electrocardiographic changes were highest in the diabetic men with the phenotypes E4/4 or E4/3 (25% (95% confidence interval 18% to 32%) and 50% (42% to 58%) respectively), although the difference between the phenotype groups was not significant. The prevalence of angina pectoris was 69% (61% to 77%) in men with the phenotypes E4/4 or E4/3 (p = 0.005 compared with other phenotypes), 41% (33% to 49%) in men with phenotype E3/3, and 47% (39% to 55%) in those with phenotypes E2/2 or E2/3. Similarly, the simultaneous presence of angina pectoris and ischaemic electrocardiographic changes was highest in the diabetic men with the phenotypes E4/4 or E4/3 (42% v 22% in those with E3/3 and 29% in those with E2/2, E2/3; p = 0.038). Overall, the prevalence of any evidence of coronary heart disease among the diabetic subjects with the phenotypes E4/4 or E4/3 was 81% (p = 0.011 compared with other phenotypes), 58% in those with phenotype E3/3, and 53% in those with phenotypes E2/2 or E3/3. CONCLUSION--Apolipoprotein E phenotypes E4/4 and E4/3 modulate the risk of coronary heart disease in men with non-insulin dependent diabetes.

Full text

PDF
1159

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Assmann G., Schmitz G., Menzel H. J., Schulte H. Apolipoprotein E polymorphism and hyperlipidemia. Clin Chem. 1984 May;30(5):641–643. [PubMed] [Google Scholar]
  2. Basu S. K., Ho Y. K., Brown M. S., Bilheimer D. W., Anderson R. G., Goldstein J. L. Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes. J Biol Chem. 1982 Aug 25;257(16):9788–9795. [PubMed] [Google Scholar]
  3. Cumming A. M., Robertson F. W. Polymorphism at the apoprotein-E locus in relation to risk of coronary disease. Clin Genet. 1984 Apr;25(4):310–313. doi: 10.1111/j.1399-0004.1984.tb01995.x. [DOI] [PubMed] [Google Scholar]
  4. Davignon J., Gregg R. E., Sing C. F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis. 1988 Jan-Feb;8(1):1–21. doi: 10.1161/01.atv.8.1.1. [DOI] [PubMed] [Google Scholar]
  5. Ehnholm C., Lukka M., Kuusi T., Nikkilä E., Utermann G. Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res. 1986 Mar;27(3):227–235. [PubMed] [Google Scholar]
  6. Eto M., Watanabe K., Ishii K. Reciprocal effects of apolipoprotein E alleles (epsilon 2 and epsilon 4) on plasma lipid levels in normolipidemic subjects. Clin Genet. 1986 Jun;29(6):477–484. doi: 10.1111/j.1399-0004.1986.tb00547.x. [DOI] [PubMed] [Google Scholar]
  7. Eto M., Watanabe K., Iwashima Y., Morikawa A., Chonan N., Oshima E., Sekiguchi M., Ishii K. Increased frequency of apolipoprotein epsilon 4 allele in type II diabetes with hypercholesterolemia. Diabetes. 1987 Nov;36(11):1301–1306. doi: 10.2337/diab.36.11.1301. [DOI] [PubMed] [Google Scholar]
  8. Eto M., Watanabe K., Iwashima Y., Morikawa A., Oshima E., Sekiguchi M., Ishii K. Apolipoprotein E polymorphism and hyperlipemia in type II diabetics. Diabetes. 1986 Dec;35(12):1374–1382. doi: 10.2337/diab.35.12.1374. [DOI] [PubMed] [Google Scholar]
  9. Faber O. K., Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes. 1977 Jul;26(7):605–610. doi: 10.2337/diab.26.7.605. [DOI] [PubMed] [Google Scholar]
  10. Gregg R. E., Zech L. A., Schaefer E. J., Brewer H. B., Jr Type III hyperlipoproteinemia: defective metabolism of an abnormal apolipoprotein E. Science. 1981 Feb 6;211(4482):584–586. doi: 10.1126/science.7455696. [DOI] [PubMed] [Google Scholar]
  11. HAVEL R. J., EDER H. A., BRAGDON J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955 Sep;34(9):1345–1353. doi: 10.1172/JCI103182. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heding L. G. Radioimmunological determination of human C-peptide in serum. Diabetologia. 1975 Dec;11(6):541–548. doi: 10.1007/BF01222104. [DOI] [PubMed] [Google Scholar]
  13. Hui D. Y., Harmony J. A., Innerarity T. L., Mahley R. W. Immunoregulatory plasma lipoproteins. Role of apoprotein E and apoprotein B. J Biol Chem. 1980 Dec 25;255(24):11775–11781. [PubMed] [Google Scholar]
  14. Imari Y., Koga S., Ibayashi H. Phenotypes of apolipoprotein E and abnormalities in lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1988 Dec;37(12):1134–1138. doi: 10.1016/0026-0495(88)90189-8. [DOI] [PubMed] [Google Scholar]
  15. Jauhiainen M., Laitinen M., Marniemi J., Liippo K., Penttilä I., Hietanen E. Preparation of soluble apolipoproteins A-I, B, and C-II by a chromatofocusing column method, and evaluation of their concentrations in serum in pulmonary disease. Clin Chem. 1983 Oct;29(10):1731–1735. [PubMed] [Google Scholar]
  16. Kesäniemi Y. A., Ehnholm C., Miettinen T. A. Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest. 1987 Aug;80(2):578–581. doi: 10.1172/JCI113107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kuusi T., Nieminen M. S., Ehnholm C., Yki-Järvinen H., Valle M., Nikkilä E. A., Taskinen M. R. Apoprotein E polymorphism and coronary artery disease. Increased prevalence of apolipoprotein E-4 in angiographically verified coronary patients. Arteriosclerosis. 1989 Mar-Apr;9(2):237–241. doi: 10.1161/01.atv.9.2.237. [DOI] [PubMed] [Google Scholar]
  18. Laakso M., Pyörälä K., Voutilainen E., Marniemi J. Plasma insulin and serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetic and non-diabetic subjects. Am J Epidemiol. 1987 Apr;125(4):611–621. doi: 10.1093/oxfordjournals.aje.a114574. [DOI] [PubMed] [Google Scholar]
  19. Laakso M., Rönnemaa T., Pyörälä K., Kallio V., Puukka P., Penttilä I. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in Finland. Diabetes Care. 1988 Jun;11(6):449–463. doi: 10.2337/diacare.11.6.449. [DOI] [PubMed] [Google Scholar]
  20. Laakso M., Voutilainen E., Pyörälä K., Sarlund H. Association of low HDL and HDL2 cholesterol with coronary heart disease in noninsulin-dependent diabetics. Arteriosclerosis. 1985 Nov-Dec;5(6):653–658. doi: 10.1161/01.atv.5.6.653. [DOI] [PubMed] [Google Scholar]
  21. Lenzen H. J., Assmann G., Buchwalsky R., Schulte H. Association of apolipoprotein E polymorphism, low-density lipoprotein cholesterol, and coronary artery disease. Clin Chem. 1986 May;32(5):778–781. [PubMed] [Google Scholar]
  22. Leren T. P., Børresen A. L., Berg K., Hjermann I., Leren P. Increased frequency of the apolipoprotein E-4 isoform in male subjects with multifactorial hypercholesterolemia. Clin Genet. 1985 May;27(5):458–462. doi: 10.1111/j.1399-0004.1985.tb00231.x. [DOI] [PubMed] [Google Scholar]
  23. Madsbad S., Alberti K. G., Binder C., Burrin J. M., Faber O. K., Krarup T., Regeur L. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J. 1979 Nov 17;2(6200):1257–1259. doi: 10.1136/bmj.2.6200.1257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mahley R. W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988 Apr 29;240(4852):622–630. doi: 10.1126/science.3283935. [DOI] [PubMed] [Google Scholar]
  25. Menzel H. J., Kladetzky R. G., Assmann G. Apolipoprotein E polymorphism and coronary artery disease. Arteriosclerosis. 1983 Jul-Aug;3(4):310–315. doi: 10.1161/01.atv.3.4.310. [DOI] [PubMed] [Google Scholar]
  26. Penttilä I. M., Voutilainen E., Laitinen P., Juutilainen P. Comparison of different analytical and precipitation methods for direct estimation of serum high-density lipoprotein cholesterol. Scand J Clin Lab Invest. 1981 Jun;41(4):353–360. doi: 10.3109/00365518109092057. [DOI] [PubMed] [Google Scholar]
  27. Pepe M. G., Curtiss L. K. Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. J Immunol. 1986 May 15;136(10):3716–3723. [PubMed] [Google Scholar]
  28. Pyörälä K., Laakso M., Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev. 1987 Apr;3(2):463–524. doi: 10.1002/dmr.5610030206. [DOI] [PubMed] [Google Scholar]
  29. Pyörälä K., Salonen J. T., Valkonen T. Trends in coronary heart disease mortality and morbidity and related factors in Finland. Cardiology. 1985;72(1-2):35–51. doi: 10.1159/000173839. [DOI] [PubMed] [Google Scholar]
  30. Riepponen P., Marniemi J., Rautaoja T. Immunoturbidimetric determination of apolipoproteins A-1 and B in serum. Scand J Clin Lab Invest. 1987 Nov;47(7):739–744. [PubMed] [Google Scholar]
  31. Sing C. F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985 Mar;37(2):268–285. [PMC free article] [PubMed] [Google Scholar]
  32. Utermann G., Hardewig A., Zimmer F. Apolipoprotein E phenotypes in patients with myocardial infarction. Hum Genet. 1984;65(3):237–241. doi: 10.1007/BF00286509. [DOI] [PubMed] [Google Scholar]
  33. Utermann G., Kindermann I., Kaffarnik H., Steinmetz A. Apolipoprotein E phenotypes and hyperlipidemia. Hum Genet. 1984;65(3):232–236. doi: 10.1007/BF00286508. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES